Home / Pharmaceutical / Anti-Inflammatory Therapeutics Market By Drug Type (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Biologics, Immune Selective Anti-Inflammatory Derivatives (ImSAIDs)), By Indication (Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, Inflammatory Bowel Disease (IBD), Psoriatic Arthritis, Gout) - Growth, Future Prospects & Competitive Analysis, 2018 - 2026

Anti-Inflammatory Therapeutics Market By Drug Type (Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroids, Biologics, Immune Selective Anti-Inflammatory Derivatives (ImSAIDs)), By Indication (Rheumatoid Arthritis, Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, Inflammatory Bowel Disease (IBD), Psoriatic Arthritis, Gout) - Growth, Future Prospects & Competitive Analysis, 2018 - 2026


Published: Apr 2018

Industry Outlook

Anti-inflammatory therapeutics market expected to reach by US$ 130.6 Bn by 2026 with CAGR of 8.5% during the forecast period from 2018 to 2026. Biologics and immune selective anti-inflammatory derivatives (ImSAIDs) are the promising drugs classes playing major role in the market. North America clearly holds major share in the global anti-inflammatory therapeutics market, as the key companies headquartered in the region. Non-steroidal anti-inflammatory drugs are used for the treatment of chronic and acute pain. Either its headache or migraines, ligament sprain, menstrual pain, and rheumatoid arthritis, anti-inflammatory drugs can treat faster as compared to other drugs. They are equipped for bringing down the level of prostaglandins, the chemicals are responsible for reducing pain, swelling, and inflammation.

Rising incidence of respiratory and autoimmune diseases, expanding investments in Asia-Pacific and Europe and a substantial number of biologics in the expansion pipeline will drive the development of global anti-inflammatory therapeutics market. Factors such as, the presence of recognized markets for biologics and corticosteroids, larger acceptance of OTC NSAIDs, for example, naproxen and ibuprofen, in countries like Indian and China would additionally enhance the market growth in Asia Pacific region.

The United States is leading market in North America at the global level, and Japan is the foremost market for biologic drugs in Asia Pacific market. While United Kingdom is projected to lead the market in Europe. Moreover, in Japan, the administration is currently focusing on the establishment of viable generic drugs. Furthermore, China anticipated to rise as the new market front-runner in Asia Pacific market by 2026 owing to rapidly developing economy, developing healthcare facilities and immense patient base. In India, the introduction of biosimilars and continuously improving healthcare expenses will be the main variables encouraging the development of anti-inflammatory therapeutics market.

"Corticosteroids drugs boosting the growth of anti-inflammatory therapeutics market"

Currently, corticosteroids are the largest drug type by value and estimated to retain its prominence and biologics to record highest double-digit CAGR throughout the forecast period from 2018-2026. According to WHO the prevalence of rheumatoid arthritis contrasts between 0.3% and 1% which is more typical in women. About 1.5 million people in the United States have rheumatoid arthritis (RA). Corticosteroids are used to treat systemic lupus, severe psoriasis and to suppress the immune system.

"IBD segment by indication to record highest double digit CAGR during the forecast period"

According to CDC (Centers for Disease Control and Prevention), in the US, it is presently projected that around 1 Mn to1.3 Mn people affected by IBD. Moreover, studies from various nations exhibit that the incidence of IBD is growing, particularly in adolescence. Right now, the most elevated yearly incidence of IBD (Inflammatory bowel disease) in Europe was 12.7 for every 100,000 person-years for CD (Crohn’s Disease) and 24.3 for every 100,000 person-years for UC (Ulcerative Colitis). In North America, the yearly incidence of IBD was 19.2 for every 100,000 men a long time for UC and 20.2 for every 100,000 person-years for the CD. Whereas in Asia and the Middle East it was 6.3 for every 100,000 person-years for UC and 5.0 for every 100,000 person-years for the CD. The maximum prevalence for UC was 505 for every 100,000 people in Europe and 249 for every 100,000 people in North America. The yearly prevalence of CD was 322 for every 100,000 people in Europe and 319 for every 100,000 people in North America. So, it is expected that these factors will encourage the development of anti-inflammatory therapeutics market.  

Historical & Forecast Period

This detailed study offers the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded Annual Growth Rate (CAGR) for each segment is calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

Anti-inflammatory therapeutics market study offers the existing market dynamics along with quantitative analysis of the global market. The report explains the detailed outline of global anti-inflammatory therapeutics market by classifying the market in terms of drug type, indication, and geography. The objective of publishing this widespread research report is to support the healthcare professionals and market investors in making better conclusions and strategic initiatives in the anti-inflammatory therapeutics market.

ATTRIBUTE DETAILS
Research Period  2016-2026
Base Year 2017
Forecast Period  2018-2026
Historical Year  2016
Unit  USD Billion
Segmentation

 Drug Types Segment (2016–2026; US$ Bn)
 • Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
 • Corticosteroids
 • Biologics
 • Immune Selective Anti-inflammatory Derivatives (ImSAIDs)

 Indication Segment (2016–2026; US$ Bn)
 • IBD (Inflammatory bowel disease)
 • COPD (Chronic obstructive pulmonary disease)
 • Multiple Sclerosis
 • Rheumatoid Arthritis
 • Psoriatic Arthritis
 • Gout
 • Others (Osteoarthritis, Systemic lupus, Psoriasis)

 Geography Segment (2016–2026; US$ Bn)
 • North America (U.S., Canada)
 • Europe (U.K., Germany, France, Italy, Spain, Rest of Europe)
 • Asia Pacific (Japan, China, India, Rest of APAC)
 • Latin America (Brazil, Mexico)
 • Middle East and Africa (GCC, Rest of Middle East and Africa)

This detailed study further defines the major qualitative market assessment factors including main market driver, market trends and restraints, to help in better understanding of global anti-inflammatory therapeutics market. Each market valuation factor comprising challenges, market drivers and opportunities are widely elucidated considering the existing market scenario. This report graphically maps the market players based on their market initiatives and product offering, strategies and business strength. Moreover, the report provides attractive investment proposition based on the extensive geographical research. Key players profiled in the report include: AbbVie Inc., Amgen Inc., AstraZeneca plc, Eli Lily and Company, GlaxoSmithKline plc, Johnson & Johnson, Merck & Company, Inc., Novartis International AG, Pfizer Inc., and F. Hoffmann-La Roche AG among others.

Key questions answered in this report

  • What are the existing market trends in the anti-inflammatory therapeutics market and valuable opportunities for the players?
  • How the regulatory framework affects the global as well as the regional markets?
  • Which is the largest segment by drug type in the anti-inflammatory therapeutics market?
  • Which is the fastest growing segment by drug type in the anti-inflammatory therapeutics market?
  • Which is the largest segment by indication in the anti-inflammatory therapeutics market?
  • Which is the fastest growing segment by indication in the anti-inflammatory therapeutics market?
  • Which is the fastest growing regional market?
  • How does the FDA approval of products affect the global market?
  • What is the trends and market size in emerging markets such as Japan, Latin and America?

TABLE 1 Global Anti-inflammatory Therapeutics Market Portraiture
TABLE 2 Global Anti-inflammatory Therapeutics Market, by Drug Type, 2016 – 2026 (US$ Bn)
TABLE 3 Global Anti-inflammatory Therapeutics Market, by Indication, 2016 – 2026 (US$ Bn)
TABLE 4 Global Anti-inflammatory Therapeutics Market, by Geography, 2016 – 2026 (US$ Bn)
TABLE 5 North America Anti-inflammatory Therapeutics Market, by Drug Type, 2016 – 2026 (US$ Bn)
TABLE 6 North America Anti-inflammatory Therapeutics Market, by Indication, 2016 – 2026 (US$ Bn)
TABLE 7 North America Anti-inflammatory Therapeutics Market, by Country, 2016 – 2026 (US$ Bn)
TABLE 8 Europe Anti-inflammatory Therapeutics Market, by Drug Type, 2016 – 2026 (US$ Bn)
TABLE 9 Europe Anti-inflammatory Therapeutics Market, by Indication, 2016 – 2026 (US$ Bn)
TABLE 10 Europe Anti-inflammatory Therapeutics Market, by Country, 2016 – 2026 (US$ Bn)
TABLE 11 Asia Pacific Anti-inflammatory Therapeutics Market, by Drug Type, 2016 – 2026 (US$ Bn)
TABLE 12 Asia Pacific Anti-inflammatory Therapeutics Market, by Indication, 2016 – 2026 (US$ Bn)
TABLE 13 Asia Pacific Anti-inflammatory Therapeutics Market, by Country, 2016 – 2026 (US$ Bn)
TABLE 14 Latin America Anti-inflammatory Therapeutics Market, by Drug Type, 2016 – 2026 (US$ Bn)
TABLE 15 Latin America Anti-inflammatory Therapeutics Market, by Indication, 2016 – 2026 (US$ Bn)
TABLE 16 Latin America Anti-inflammatory Therapeutics Market, by Country, 2016 – 2026 (US$ Bn)
TABLE 17 Middle East and Africa Anti-inflammatory Therapeutics Market, by Drug Type, 2016 – 2026 (US$ Bn)
TABLE 18 Middle East and Africa Anti-inflammatory Therapeutics Market, by Indication, 2016 – 2026 (US$ Bn)
TABLE 19 Middle East and Africa Anti-inflammatory Therapeutics Market, by Country, 2016 – 2026 (US$ Bn)
TABLE 20 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 21 Amgen Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 22 AstraZeneca plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 23 Eli Lily and Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 24 GlaxoSmithKline plc: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 25 Johnson & Johnson: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 26 Merck & Company, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 27 Novartis International AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 28 AbbVie Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
TABLE 29 F. Hoffmann-La Roche AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +